Olympus Corp
TSE:7733

Watchlist Manager
Olympus Corp Logo
Olympus Corp
TSE:7733
Watchlist
Price: 2 018 JPY -0.12% Market Closed
Market Cap: 2.3T JPY

Olympus Corp
Investor Relations

Olympus Corporation, originating from the heart of Japan in 1919, has evolved into a global powerhouse, particularly revered for its contributions to the field of optics and imaging. Initially carving its reputation through crafting precision microscope lenses, Olympus seamlessly expanded its capabilities into the realms of endoscopy and digital imaging. This strategic pivot not only defined its legacy but firmly anchored its presence in the medical world, where it became a leader in endoscopic technology. The company adeptly leveraged its expertise to revolutionize medical diagnostics and treatment, helping medical professionals see and diagnose better—enhancing both physician dexterity and patient outcomes.

Revenue for Olympus is predominantly driven by its Medical Business sector, which constitutes a significant portion of its overall profits, underscoring its transformation from a diversified manufacturer to a specialized player in healthcare technology. They are deeply committed to R&D, funneling substantial resources to innovate and bolster their portfolio in medical devices, particularly in fields like therapeutic interventions. While imaging products for consumers have historically been a notable segment, the shift toward medical technology aligns with broader market demands and ensures sustainable growth. This focus demonstrates Olympus's intent to maximize its competitive advantages, allowing it to remain at the forefront of its niche industries and effectively respond to global healthcare challenges.

Show more
Loading

Earnings Calls

2025 Q3
Feb 7, 2025
Show Transcript
Previous
Next
Graham Corporation Reports Strong Growth and Strategic Initiatives in Q3 Earnings Call
2025 Q3
Feb 7, 2025

In the third quarter, Graham Corporation achieved $47 million in sales, growing 7.3% year-over-year, driven by key sectors like defense, which rose 11%. Gross margins improved to 24.8%, benefiting from better execution and pricing. Adjusted EBITDA surged 36% to $4 million. Looking forward, the company anticipates fiscal 2025 revenue between $200 million and $210 million, reflecting an 11% growth. Adjusted EBITDA is expected to reach $18 million to $21 million, equating to a 9.5% margin. Graham also aims for an organic growth rate of 8% to 10% annually through strategic investments and acquisitions.

Show Full Analysis

Management

Mr. Yasuo Takeuchi
Representative Executive Officer, ESG Officer & Executive Chairman
No Bio Available
Mr. Andre Roggan
Executive Officer & CTO
No Bio Available
Mr. Tetsuo Kobayashi
Executive Officer and Chief Manufacturing & Supply Officer
No Bio Available
Mr. Frank Drewalowski
Executive Officer & Endoscopic Solutions Division Head
No Bio Available
Ms. Gabriela Kaynor
Executive Officer & Chief Strategy Officer
No Bio Available
Tatsuya Izumi
Executive Officer & CFO
No Bio Available
Stephen Kneebone
Corporate Officer & Chief Information Officer
No Bio Available
Mr. Takaaki Sakurai
Vice President of Investor Relations
No Bio Available
Mr. Neil Boyden Tanner
Executive Officer & Global General Counsel
No Bio Available
Shigeto Ohtsuki
Executive Officer & Chief Human Resources Officer
No Bio Available

Contacts

Address
TOKYO-TO
Shinjuku
Shinjuku Monolith, 2-3-1, Nishi-Shinjuku
Contacts
+81333402111.0
www.olympus.co.jp